1160950-90-2

Upstream product

• 223718-30-7 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one 
• 224779-27-5 tert-butyl 3-hydroxy-1,2,3,6-tetrahydropyridine-N-carboxylate 
• 1334628-88-4 C₂₀H₁₇NO₆ 
• 1160950-71-9 C₂₅H₂₁NO₆ 
• 1160952-36-2 C₂₇H₂₃NO₇ 
• 1160950-89-9 3',6-dimethoxy-N-(8-methyl-2-oxo-7-(1,2,3,6-tetrahydropyridin-3-yloxy)-2H-chromen-3-yl)biphenyl-3-carboxamide 
• 74-88-4 methyl iodide 
• 1308889-23-7 tert-butyl 5-(3-(3',6-dimethoxybiphenyl-3-ylcarboxamido)-8-methyl-2-oxo-2H-chromen-7-yloxy)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1350834-62-6 C₁₂H₁₁NO₄ 
• 1083313-80-7 3',6-dimethoxy-[1,1'-biphenyl]-3-carbonyl chloride 
• 1083313-05-6 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid 

Relevant academic research and scientific papers

Engineering an antibiotic to fight cancer: Optimization of the novobiocin scaffold to produce anti-proliferative agents

Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ?700- fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure- activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.